Results 61 to 70 of about 5,935 (185)

Stent thrombosis with an aneurysm 7 years after a drug eluting stent implantation

Indian Heart Journal, 2014
We report a case of very late stent thrombosis 7 years post sirolimus eluting stent implantation presenting as ST elevation MI while on dual antiplatelet therapy. Angiography revealed an aneurysm at the proximal end of the stent.
Pritam Patil, Arvind Sethi, Upendra Kaul
doaj   +1 more source

Comprehensive Review of Antiplatelet Therapy in Secondary Prevention of Myocardial Infarction: Mechanisms, Clinical Evidence, and Future Directions

Cardiovascular Therapeutics, Volume 2026, Issue 1, 2026.
Atherosclerotic cardiovascular disease (ASCVD), particularly myocardial infarction (MI), is the leading cause of mortality and morbidity worldwide. The pathophysiology of MI involves atherosclerotic plaque rupture with thrombus formation, interrupting myocardial blood supply with subsequent myocardial necrosis.
May Thu Kyaw, Arkar Moe, Irfan Ahmad
wiley   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors

British Journal of Pharmacology, Volume 182, Issue S1, Page S259-S306, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Doriano Fabbro, Chloe J. Peach, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Annie Beuve, Peter Brouckaert, Clare Bryant, John C. Burnett, Richard W. Farndale, Andreas Friebe, John Garthwaite, Adrian J. Hobbs, Gavin E. Jarvis, Laura Kilpatrick, Doris Koesling, Michaela Kuhn, Birgit Leitinger, David MacEwan, Tom P. Monie, Lincoln R. Potter, Michael Russwurm, Harald H. H. W. Schmidt, Johannes‐Peter Stasch, Scott A. Waldman   +31 more
wiley   +1 more source

Bilateral subconjunctival hemorrhage secondary to abciximab use: case report

, 2019
CONTEXT: There are no reports on cases of subconjunctival hemorrhage due to use of glycoprotein IIb/IIIa inhibitors. In this report, we present the case of a patient with bilateral subconjunctival hemorrhage after receiving abciximab.
Muhammet Raşit Sayın (4701283), Selim Kul (4701280)   +1 more
core   +1 more source

Abciximab in the treatment of coronary artery disease [PDF]

, 2013
Antiplatelet therapy constitutes a cornerstone in the strategies aimed at the effective management of acute coronary syndrome. Abciximab is the oldest and most commonly used intravenous antiplatelet agent in this context, in particular when an invasive ...
Maxwell, Ryan, Murdoch, Dale, Jayasinghe, Rohan   +2 more
core   +2 more sources

Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.

, 2003
BACKGROUND: Trials of platelet glycoprotein IIb/IIIa inhibitors as adjuncts to primary percutaneous coronary intervention for acute myocardial infarction (MI) have shown improved early clinical and angiographic outcomes with treatment.
Tcheng, James E, Turco, Mark, Effron, Mark B, Stuckey, Thomas, Kandzari, David E, Grines, Cindy L, Fahy, Martin, Cox, David A, Stone, Gregg W, Lansky, Alexandra J, Griffin, John J, Guagliumi, Giulio, Garcia, Eulogio, Mehran, Roxana   +13 more
core   +2 more sources

Comparison between Intracoronary Abciximab and Intravenous Eptifibatide Administration during Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction

Journal of Tehran University Heart Center, 2015
Background: Administration of glycoprotein IIb/IIIa inhibitors is an effective adjunctive treatment strategy during primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI).
MohammadHasan Namazi, Morteza Safi, Hosein Vakili, Habibollah Saadat, Esfandiar Karimi, Ramin Khameneh-Bagheri   +5 more
doaj  

Biomimetic Cell Membrane‐Coated Scaffolds for Enhanced Tissue Regeneration

Advanced Materials, Volume 37, Issue 40, October 9, 2025.
This review examines the development and use of cell membrane‐coated scaffolds in tissue engineering. Bioinspired phospholipid and glycocalyx coatings enhance anti‐fouling, anti‐thrombogenic, and selective molecular recognition properties. Native cell membrane coatings further support cell‐specific interactions, immune modulation, and reduced bacterial
Carmen Alvarez‐Lorenzo, Alejandro Ramirez‐Romero, Diana Peixoto, Maria Vivero‐Lopez, Isabel Rodríguez‐Moldes, Angel Concheiro   +5 more
wiley   +1 more source

Eptifibatide and abciximab inhibit insulin-induced focal adhesion formation and proliferative responses in human aortic smooth muscle cells

Cardiovascular Diabetology, 2008
Background The use of abciximab (c7E3 Fab) or eptifibatide improves clinical outcomes in diabetics undergoing percutaneous coronary intervention. These β3 integrin inhibitors antagonize fibrinogen binding to αIIbβ3 integrins on platelets and ligand ...
Huang Jianhua, Zhao Renyi, Pathak Alokkumar, Stouffer George A   +3 more
doaj   +1 more source

Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial.

, 2004
CONTEXT: The optimal pharmacological strategy for bridging the delay between admission and performance of percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (MI) is not known.
Kastrati, A;Mehilli, J;Schlotterbeck, K;Dotzer, F;Dirschinger, J;Schmitt, C;Nekolla, SG;Seyfarth, M;Martinoff, S;Markwardt, C;Clermont, G;Gerbig, HW;Leiss, J;Schwaiger, M;Schömig, A
core   +1 more source